论文部分内容阅读
目的:筛选与评价安全、有效、可长期口服的防治骨质疏松(OP)药物。方法:分别用中药壮骨胶囊及西药钙尔奇D治疗105例绝经后OP患者,选择骨密度(BMD)、血清骨钙素(BGP)、降钙素(CT)、雌二醇(E2)、碱性磷酸酶(AKP)、钙(Ca)、磷(P)等为观察指标。结果:中药治疗后BMD及血清CT、E2较治疗前升高,西药治疗后BMD、BGP、E2均较治疗前升高。其中中药治疗后较治疗前BMD平均上升5.42%,而西药治疗后较治疗前升高3.07%。血AKP、Ca、P两组治疗前后无显著性差异。治疗前Ⅲ度OP患者的BMD明显低于Ⅰ、Ⅱ度。中药治疗后Ⅱ、Ⅲ度OP患者的BMD低于Ⅰ度;60岁年龄组的BMD显著低于40岁年龄组。结论:中药壮骨胶囊及西药钙尔奇D对绝经后OP治疗均有效,前者疗效似更好。
Objective: To screen and evaluate the safe, effective and long-term oral anti-osteoporosis (OP) drugs. Methods: A total of 105 patients with postmenopausal OP were treated with Zhuanggu capsules and western medicine. The bone mineral density (BMD), serum BGP, calcitonin (CT), estradiol (E2) , Alkaline phosphatase (AKP), calcium (Ca) and phosphorus (P) were observed. Results: The BMD, serum CT and E2 of Chinese medicine were higher than those before treatment, and the levels of BMD, BGP and E2 increased after treatment with Western medicine. Among them, BMD increased by 5.42% after traditional Chinese medicine treatment than before treatment, but increased 3.07% after western medicine treatment than before treatment. Blood AKP, Ca, P two groups before and after treatment no significant difference. Before treatment, patients with OP Ⅲ degree of BMD was significantly lower than Ⅰ, Ⅱ degrees. The BMD of patients with stage II and III OP after Chinese medicine treatment was lower than that of degree Ⅰ. The BMD of 60-year-old group was significantly lower than that of 40-year-old group. Conclusion: Chinese medicine Zhuanggu capsule and western medicine Caerch of the D treatment of postmenopausal OP are effective, the former effect is better.